2021-01-06,"SHAREHOLDER ALERT: WeissLaw LLP Reminds ANCN, PRVL, WORK, and GNBF Shareholders About Its Ongoing Investigations"
2020-12-30,"SHAREHOLDER ALERT: WeissLaw LLP Reminds ANCN, PRVL, TLRY, and GNBF Shareholders About Its Ongoing Investigations"
2020-12-24,"Lifshitz Law Firm, P.C. Announces Investigation of ANCN, BEAT, HMSY, SNCA, SPWH, TCP, TRP, TLRY, and APHA"
2020-12-22,"SHAREHOLDER ALERT: WeissLaw LLP Reminds ANCN, PRVL, BRPA, and TPGY Shareholders About Its Ongoing Investigations"
2020-12-21,"Moore Kuehn Encourages BEAT, AJRD, ANCN, and RNET Investors to Contact Law Firm"
2020-12-17,"SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Anchiano Therapeutics Ltd. Merger"
2020-12-16,"The Daily Biotech Pulse: Novartis Gets Adcom Backing, Sio Gene Data, 2 IPOs, BioNTech Clinches China Vaccine Supply Deal"
2020-12-15,SHAREHOLDER ALERT: WeissLaw LLP Investigates Anchiano Therapeutics Ltd.
2020-12-15,Anchiano Therapeutics and Chemomab Announce Entry Into Definitive Merger Agreement
2020-10-08,All You Need to Know About Anchiano Therapeutics Ltd. Sponsored ADR (ANCN) Rating Upgrade to Buy
2020-05-26,Anchiano Appoints Stan Polovets as Chairman of the Board
2020-05-11,Anchiano Therapeutics Reports First Quarter 2020 Financial Results
2020-05-05,Anchiano Appoints Steve DiPalma as Chief Financial Officer
2020-04-17,Anchiano to Hold Virtual Annual Meeting of Shareholders
2020-03-18,Anchiano Therapeutics Reports Year-End 2019 Financial Results
2020-01-17,Anchiano Therapeutics Announces Record Date for 2020 Annual General Meeting of Shareholders
2019-11-15,Anchiano Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate Update
2019-11-15,Anchiano Discontinues Phase 2 Codex Study Evaluating Inodiftagene Vixteplasmid in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC); Company Focuses on Advancing Pan-RAS Inhibitor Program
2019-10-24,Anchiano Therapeutics Chairman Stephen Hoffman Steps Down from Board
2019-09-23,Anchiano Therapeutics Enters into An Exclusive Option To License Agreement for Novel Pan-RAS Inhibitor and PDE10/-catenin Inhibitor Programs
2019-09-20,Anchiano Therapeutics to Present at the Ladenburg Thalmann Healthcare Conference
2019-09-03,Anchiano Therapeutics to Present at the Baird 2019 Global Healthcare Conference
2019-08-05,Anchiano Therapeutics Reports Second Quarter 2019 Financial Results
2019-06-18,Anchiano Therapeutics Delists Ordinary Shares from the Tel Aviv Stock Exchange
2019-05-29,Anchiano Therapeutics Announces Appointment of Salar Roshan as Head of Business Development
2019-05-22,Anchiano Therapeutics Reports First Quarter 2019 Financial Results
2019-03-14,Anchiano Therapeutics to Present at the Oppenheimer 29th Annual Healthcare Conference
2019-03-14,Anchiano Therapeutics Initiates Process to Voluntarily Delist its Ordinary Shares from the Tel Aviv Stock Exchange
2019-03-12,Anchiano Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results
2019-02-14,Anchiano Therapeutics Announces Closing of $30.5 Million Initial Public Offering
2019-02-12,Anchiano Therapeutics' stock set to close well below its IPO price
2019-02-12,Anchiano Therapeutics IPO prices below assumed price
2019-02-12,Anchiano Therapeutics Announces Pricing of $30.5 Million Initial Public Offering
2019-02-10,IPO Outlook For The Week: Biotechs And Another Virgin Group Addition
